The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJules Bordet Institute
About this trial
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery
Eligibility criteria
Qualifiers
Age above 18 years.
Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT)
Naïve for treatment or after neoadjuvant chemotherapy
Scheduled for liver metastasis resection
Disqualifiers
Non-resectable liver metastases
Pregnant and lactating women
Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Trial design
Treatments tested in this trial
- FAPI PET/CT
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov